Current major international guidelines for the treatment of hypertension recommend systolic blood pressure medications to control to below 140 mmHg, but there is no accepted definition of the target blood pressure reduction value as well as the lower target boundary. Randomized controlled trials in hypertension have confirmed the cardiovascular benefits of reducing systolic blood pressure to below 160 mmHg. A new study has explored cardiovascular outcomes at different treatment blood pressure levels, exploring the relationship between clinical outcomes and systolic blood pressure. The clinical trial looked at 10,705 high-risk hypertensive patients divided by systolic blood pressure level into four strata: >140 mm Hg, 130 to 140 mm Hg, 120 to 130 mm Hg, and 110 to 120 mm Hg. The association between each blood pressure stratum and the occurrence of cardiovascular death or nonfatal myocardial infarction or stroke was examined. The results of the study confirmed that among high-risk hypertensive patients, major cardiovascular events were significantly lower in patients with comprehensive treatment-controlled systolic blood pressure <140 mmHg than in patients with systolic blood pressure >140 mmHg. In contrast, cardiac coronary events were increased in patients with systolic blood pressure below 120 mmHg. Systolic blood pressure control of 130-139 mmHg is beneficial for the protection of renal function in patients. Blood pressure control does not have to be normal to be good, and additional studies have demonstrated that perioperative hypotension, even under anesthesia, significantly increases postoperative mortality in elderly patients. In conclusion, blood pressure control of 130 to 140 mmHg is most beneficial in high-risk hypertensive patients.